UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

Toward a pathophysiology inspired treatment of VEXAS syndrome

Seminars in hematology, 2021-10, Vol.58 (4), p.239-246

2021

Volltextzugriff (PDF)

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience

Blood advances, 2022-02, Vol.6 (3), p.998-1003

2022

Volltextzugriff (PDF)

COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study

Cancers, 2021-10, Vol.13 (21), p.5283

2021

Volltextzugriff (PDF)

From vacuoles to VEXAS

Rheumatology (Oxford, England), 2023-12, Vol.62 (12), p.3780-3781

2023

Volltextzugriff (PDF)

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Blood, 2021-07, Vol.137 (26), p.3682-3684

2021

Volltextzugriff (PDF)

Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning

Haematologica (Roma), 2022-06, Vol.107 (6), p.1466

2022

Volltextzugriff (PDF)

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended

PloS one, 2014-09, Vol.9 (9), p.e106250

2014

Volltextzugriff (PDF)

Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry

Leukemia research, 2021-12, Vol.111, p.106673-106673, Article 106673

2021

Volltextzugriff (PDF)

P1135: EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH‐DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e62941c4-n/a

2023

Volltextzugriff (PDF)

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Blood, 2020-11, Vol.136 (Supplement 1), p.6-7

2020

Volltextzugriff (PDF)

An evaluation of glasdegib for the treatment of acute myelogenous leukemia

Expert opinion on pharmacotherapy, 2020-03, Vol.21 (5), p.523-530

2020

Volltextzugriff (PDF)

VEXAS: where do we stand 2 years later?

Current opinion in hematology, 2023-03, Vol.30 (2), p.64

2023

Volltextzugriff (PDF)

How to Transform an Exceptional Case Report Into a Therapy: Following the Frog Out of the Box

HemaSphere, 2021-09, Vol.5 (9), p.e629-n/a

2021

Volltextzugriff (PDF)

Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib

Experimental hematology, 2018-08, Vol.64, p.97-105.e4

2018

Volltextzugriff (PDF)

Acute Promyelocytic Leukemia

Cancers, 2020-12, Vol.12 (12), p.3718

2020

Volltextzugriff (PDF)

Acute myeloid leukemia in the elderly (age 70 yr or older): long‐term survivors

European journal of haematology, 2017-02, Vol.98 (2), p.134-141

2017

Volltextzugriff (PDF)

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database

Drugs & aging, 2023-05, Vol.40 (5), p.397-405

2023

Volltextzugriff (PDF)

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Nature medicine, 2018-08, Vol.24 (8), p.1167-1177

2018

Volltextzugriff (PDF)

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e19161da

2023

Volltextzugriff (PDF)

Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials

Expert opinion on emerging drugs, 2022-04, Vol.27 (2), p.169-185

2022

Volltextzugriff (PDF)

Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease

Clinical lymphoma, myeloma and leukemia, 2018-05, Vol.18 (5), p.e211-e218

2018

Volltextzugriff (PDF)

Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

British journal of haematology, 2022-02, Vol.196 (4), p.969-974

2022

Volltextzugriff (PDF)

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group

Leukemia, 2022-05, Vol.36 (5), p.1390-1400

2022

Volltextzugriff (PDF)

Chronic myelomonocytic leukemia transdifferentiation landscape: From histiocytosis to blastic plasmacytoid dendritic cell neoplasm

American journal of hematology, 2023-08, Vol.98 (8), p.1343-1345

2023

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Toward a pathophysiology inspired treatment of VEXAS syndrome

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience

COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study

From vacuoles to VEXAS

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended

Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry

P1135: EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH‐DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

An evaluation of glasdegib for the treatment of acute myelogenous leukemia

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

VEXAS: where do we stand 2 years later?

How to Transform an Exceptional Case Report Into a Therapy: Following the Frog Out of the Box

Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib

Acute Promyelocytic Leukemia

Acute myeloid leukemia in the elderly (age 70 yr or older): long‐term survivors

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials

Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease

Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group

Chronic myelomonocytic leukemia transdifferentiation landscape: From histiocytosis to blastic plasmacytoid dendritic cell neoplasm

Suchergebnisse filtern